1778.90
3.46%
Emkay
Ipca’s 4QFY26 EBITDA was ahead of our expectations (broadly in line with the consensus’). The beat was driven by higher overall sales, a marginally higher gross margin, as well as lower staff costs.
Ipca Laboratories Ltd. is trading at high day volume of 571.4K.
More from Ipca Laboratories Ltd.
Recommended